抗血管内皮生长因子Bevacizumab在眼部新生血管中的应用新进展  

Recent advances in application of Anti-vascular endothelial growth factor Bevacizumab in ocular neovascularization

作　　者：林芳[1] 高晓唯 任兵 

机构地区：[1]石河子大学医学院 [2]解放军第四七四医院眼科中心

出　　处：《国际眼科杂志》2008年第8期1644-1646,共3页International Eye Science

摘　　要：眼部新生血管性病变是致盲的主要原因之一,大量的研究证据表明血管内皮生长因子(vascular endothelial growth factor,VEGF)是新生血管形成的关键调控因子。Bevaci-zumab是世界上首个批准上市的血管内皮因子抑制剂由于其强大的抗新生血管作用,在眼科新生血管性疾病治疗中有广泛的应用前景。本文对VEGF的特性、VEGF在眼部新生血管形成中的作用和Bevacizumab作用机制、应用范围进行综述。Ocular neovascularization is the primary cause of blindness. There were extensive evidences that vascular endothelial growth factor （VEGF） was a major regulator of neovascularization. Bevacizumab, the first antivascular endothelial growth factor drug, had approved by the Food and Drug Administration. As anti-vascular endothelial growth factor drug, Bevacizumab may be beneficial to any ocular disease in which neovascularization and edema play a major role. The present paper focuses on VEGF and its role in ocular neovascularization and current anti-VEGF and Bevacizumab＇s mechanism, scope of application.

关 键 词：新生血管 血管内皮生长因子 贝伐单抗 

分 类 号：R771[医药卫生—眼科]